These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
711 related articles for article (PubMed ID: 27736844)
1. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Konecny GE; Kristeleit RS Br J Cancer; 2016 Nov; 115(10):1157-1173. PubMed ID: 27736844 [TBL] [Abstract][Full Text] [Related]
2. Advances in PARP inhibitors for the treatment of breast cancer. Dizdar O; Arslan C; Altundag K Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111 [TBL] [Abstract][Full Text] [Related]
3. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. Lau CH; Seow KM; Chen KH Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700 [TBL] [Abstract][Full Text] [Related]
4. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. Papa A; Caruso D; Strudel M; Tomao S; Tomao F J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150 [TBL] [Abstract][Full Text] [Related]
5. The current status of PARP inhibitors in ovarian cancer. McLachlan J; George A; Banerjee S Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873 [TBL] [Abstract][Full Text] [Related]
6. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Liu FW; Tewari KS Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795 [TBL] [Abstract][Full Text] [Related]
7. A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy. Zhang N; Zheng H; Gao Y; Shu T; Wang H; Cai Y J Ovarian Res; 2024 Mar; 17(1):55. PubMed ID: 38444005 [TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Turk AA; Wisinski KB Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759 [TBL] [Abstract][Full Text] [Related]
9. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. Gunderson CC; Moore KN Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679 [TBL] [Abstract][Full Text] [Related]
11. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085 [TBL] [Abstract][Full Text] [Related]
12. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788 [TBL] [Abstract][Full Text] [Related]
13. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
14. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer. Onstad M; Coleman RL; Westin SN Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746 [TBL] [Abstract][Full Text] [Related]
15. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488 [TBL] [Abstract][Full Text] [Related]
16. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency? Gourley C; Miller RE; Hollis RL; Ledermann JA Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232 [TBL] [Abstract][Full Text] [Related]
17. A review on mechanisms of resistance to PARP inhibitors. Desai C; Pathak A; Limaye S; Maniar V; Joshi A Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? Tan DS; Kaye SB Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149 [TBL] [Abstract][Full Text] [Related]
19. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. Wang L; Wang Q; Xu Y; Cui M; Han L Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293 [TBL] [Abstract][Full Text] [Related]
20. [Abnormalities of DNA repair and gynecological cancers]. Auguste A; Leary A Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]